



The Nifty previous session ended 0.86% down at 11,202.85. It opened on a positive note and got sold off around 11,350 levels followed by further down fall towards finishing off with a bearish spinning-top candle. Failing to breakout 11,350 suggests this level may continue to serve as the critical resistance in tomorrow's session as well. Downside supports are placed around 11,100 and 11,000 levels.

On the Nifty hourly chart; RSI turned down following sell off from around 11,350 levels. However, critical moving average band is still intact. Supports are placed around 11,100 and 11,000 levels.

Nifty patterns on multiple time frames suggest; failing to breakout 11,350 implies it may now get into the broader price band of 11,350-11,000.

Nifty Crucial Supports & Resistances-

Supports- 11100, 11000 Resistances- 11350, 11420

Open positional calls-

T+15 Investment Buy-
|Cash Segment| Accumulate DCB on dips around @ 82-80, TGT- 100, SL- closing below 70

T+15 Positional Buy-
|Cash Segment| Accumulate GLENMARK on dips around @ 425-420, TGT- 480, SL- closing below 390

T+5 Positional Buy-
|Cash Segment| DABUR on dips around @ 483-480, TGT- 500, SL- closing below 470

BTST Positional Buy-
|Cash Segment| LUPIN on dips around @ 856-855, TGT- 875, SL- closing below 845

Key Contents	Page No.
Conference Call Highlights	4
Result Analysis	7
Domestic News	9

Nifty Intraday Chart



Market in Retrospect

Indian equity markets reversed most of Tuesday's gains ending near the lowest point of the day, dragged lower by heavyweight Reliance Industries (down 4%).

NSE Nifty 50 ended above the 11,200 mark, down 0.86% at 11,202. The broader markets represented by the NIFTY 500 Index ended 0.50% lower, ending at 9096. NIFTY Pharma was the top gainer, gaining by 3.09%, followed by NIFTY PSU Bank gaining by 1.51%. NIFTY Energy was the top loser, losing by 1.65%.

Dr. Reddy's was the top gainer, gaining by 6.19%, followed by Indusind Bank and Tata Steel, which gained by 4.47% & 4.25% respectively. RIL was the top loser, losing by 3.72%, followed by Nestle India and HCL, which fell by 2.91% & 2.53% respectively.

The Advance: Decline ratio stood at 998:870

Market Turnover (In Crore) 29-07-2020

Name	Last	Previous
NSE Cash	62540.86	60291.20
NSE F&O	2262936.95	1755818.03
BSE Cash	3,572.04	3,202.05
BSE F&O	324.44	295.53

FII Derivatives Flow (In Crore) 28-07-2020*

Instrument	Purchase	Sale	Net
Index Future	6213.98	5220.88	993.1
Index Option	213981.26	214550.11	568.85
Stock Future	40137.24	39774.42	362.82
Stock Option	5638.79	5690.49	51.7

Institutional Flow (In Crore) 29-07-2020

Institution	Purchase	Sale	Net
FII	5725.05	6077.67	352.62
DII	4301.09	4806.71	505.62

*Data not updated till 6PM

NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Dr. Reddy'S	6.19	5.92	4953494	745448
Indusind Bank	4.47	7.20	37044658	17410670
Tata Steel	4.25	6.77	30116131	11772880
Grasim Industries	3.36	2.41	6086161	2404148
Bharti Infratel	3.15	2.02	9332794	7125049

NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Hero Motocorp	2.16	0.43	1092469	1133499
M&M	2.50	2.17	5182955	7266285
HCL	2.53	6.81	7142688	7839106
Nestle India	2.91	3.23	450505	146702
RIL	3.72	4.62	33536361	34531840

Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

Sensex Intraday Chart



Market in Detailed (Updated after 4:00 PM)

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	38071.13	421.82	1.10	0.53	8.89	16.35	1.02
Nifty	11202.85	97.70	0.86	0.63	8.63	17.27	0.12
BSE M Cap	13762.55	93.63	0.68	0.83	5.27	16.24	0.00
BSE S Cap	12972.35	54.93	0.43	0.43	3.99	18.20	0.36
Nifty MC 100	15535.05	74.95	0.48	0.72	5.43	17.44	2.98
BSE Auto	16595.73	201.06	1.20	1.78	9.79	31.72	6.31
BSE Capgoods	12823.06	31.70	0.25	0.51	0.17	7.68	26.69
BSE FMCG	11464.58	19.97	0.17	0.25	2.01	6.31	3.79
BSE Metal	7851.14	76.46	0.98	2.41	9.00	26.01	19.67
BSE Oil&Gas	13573.54	148.15	1.08	0.05	5.52	17.69	1.42
BSE Healthcare	17327.61	361.62	2.13	2.60	5.25	12.36	35.40
BSE Power	1557.01	2.19	0.14	0.41	1.93	7.91	20.99
BSE Realty	1559.83	0.52	0.03	0.65	1.41	10.22	25.65
BSE ConsDur	21453.19	194.41	0.90	1.94	5.46	7.62	5.13
BSE Bank	25067.17	3.98	0.02	3.27	3.37	3.51	24.50
BSE IT	18061.66	182.04	1.00	4.68	21.26	34.04	16.26

Bond Markets							
Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	0.59	0.01	2.26	0.84	5.02	5.55	71.33
UK	0.12	0.01	11.01	0.83	25.77	57.54	81.50
Brazil	4.66	0.02	0.47	0.28	5.54	8.97	3.67
Japan	0.02	0.00	0.00	21.05	27.78	160.53	116.08
Australia	0.88	0.04	4.79	1.46	0.79	4.79	27.63
India	5.84	0.02	0.26	0.17	1.17	4.69	9.00
Switzerland	0.52	0.01	1.34	5.08	19.68	13.38	26.87
Germany	0.49	0.01	2.76	0.82	5.11	0.20	26.34

Currency							
Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	74.80	0.05	0.06	0.05	1.04	1.17	8.12
USD Index	93.55	0.15	0.16	1.52	4.09	6.04	4.59
YUAN	7.00	0.00	0.04	0.03	1.19	1.13	1.49
GBP	1.30	0.00	0.26	1.81	5.42	3.98	6.11
EUR	1.17	0.00	0.22	1.49	4.45	7.99	5.36
YEN	105.01	0.08	0.08	2.04	2.45	1.59	3.59

Freight							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	1264.00	29.00	2.24	20.70	29.54	96.58	34.24
Baltic Dirty	513.00	3.00	0.58	4.82	10.32	63.01	18.83
SG Dubai HY	0.82	0.29	54.72	355.56	472.73	531.58	87.09

Global Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	26379.28	205.49	0.77	1.72	3.06	7.09	3.09
Nasdaq	10402.09	134.18	1.27	2.61	5.35	16.68	25.43
S&P 500	3218.44	20.97	0.65	1.19	5.41	9.49	6.54
FTSE100	6150.25	22.39	0.37	0.89	1.19	0.60	19.97
CAC40	4963.64	35.26	0.72	1.45	0.38	6.27	11.37
DAX	12831.15	0.02	0.00	2.05	4.93	15.55	3.36
Mexico IPC	37771.21	29.07	0.08	2.41	0.01	2.44	8.49
Brazil Bovespa	104109.1	368.00	0.35	0.19	8.75	25.18	0.61
Russian RTS	1263.06	5.22	0.42	0.62	1.86	10.33	6.70
Japan Nikkei	22397.11	260.27	1.15	1.41	1.83	13.28	3.61
Hang Seng	24883.14	110.38	0.45	0.70	2.39	0.97	11.47
Taiwan Index	12540.97	45.76	0.36	0.54	8.65	16.42	15.21
Shanghai Comp	3294.55	66.59	2.06	1.16	11.25	16.73	12.02
KOSPI	2263.16	6.17	0.27	1.55	8.11	16.20	11.51
Malaysia KLCI	1611.42	1.48	0.09	1.54	7.83	16.74	1.90
Jakarta Comp	5111.11	1.88	0.04	0.02	4.27	11.91	18.86
Philippine SE	5966.27	39.16	0.66	1.62	2.28	5.71	27.14
Thai Exch	1338.35	2.57	0.19	1.47	0.60	5.60	22.10

Indian Indices							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	41.36	0.32	0.78	1.29	4.18	174.63	27.27
BRENT Crude	43.69	0.46	1.06	1.38	4.37	55.83	28.13
Natural Gas	1.79	0.01	0.67	6.37	4.62	18.58	25.56

LME							
Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1955.80	2.67	0.14	4.51	10.32	14.14	37.07
Silver(\$/Ounce)	24.30	0.08	0.34	5.75	36.18	58.99	47.76
Aluminium	1685.25	15.25	0.91	1.51	6.24	15.01	5.18
Copper	6490.00	63.50	0.99	0.83	9.02	24.93	9.24
Zinc	2240.64	12.14	0.54	0.22	10.35	16.44	8.47
Lead	1850.90	13.31	0.72	1.31	4.16	14.29	10.03

Agro Commodities							
Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	110.20	0.55	0.50	1.71	10.09	3.38	4.22
Cotton	61.80	0.69	1.13	1.18	3.64	5.32	6.46
Sugar	11.97	0.04	0.33	0.93	1.70	17.24	11.40
Wheat	530.50	7.00	1.34	0.75	9.04	1.82	0.09
Soybean	887.50	0.00	0.00	0.89	3.02	5.12	6.78

Ultratech Cement Ltd.

- Management believes FY21e would be one of the best year in terms of profitability for cement industry
- Industry demand declined by ~33-35% in Q1FY21, company witnessed pick up of cement demand in regions of East, Central, North India, good demand was witnessed in Kerala and Tamil Nadu while demand was weak in West India, Andhra Pradesh, Telangana and Karnataka
- Average capacity utilization for the company in Q1FY21 was ~46% & in July 2020 has been around ~60-65%
- Trade sales mix in Q1FY21 at 78% (at record levels)
- Demand in Q1FY21 was boosted by individual house building segment (35% of total demand) which reported YoY growth while urban and institutional demand remained muted
- Management expects strong rural demand to continue on the back of strong rural cash flows
- Expect pickup in demand in Orissa (rehabilitation work post cyclone and IHB) and West Bengal (due to expected pre-election demand)
- Management sounded confident on recovery from urban real estate post November 2020 with return of labour after Diwali. Project works and state induced capex is also expect to recover
- In Q1FY21 cement prices were up 7% QoQ but are down 4-5% since then due to monsoons
- Expect to commission ongoing expansion in Bihar (0.60 MMT) and West Bengal (0.60 MMT) by early FY22e. 2.30 MMT clinker unit in Uttar Pradesh (Super Dalla) is also expected to commission in FY22e
- Work on Pali project is expected to start in FY22e and expect to commission by Oct-Dec'2022
- Fixed overheads for FY20 was ~INR5000cr. Management targets fixed cost reduction of ~INR500cr on an annualized basis for existing capacities. In Q1FY21 fixed cost was down by 21% (YoY) at INR989cr vs INR1231cr (YoY)
- Part of the cost reduction will happen from lower advertisement expenditure, travel expenses etc.
- Expect to receive cash inflow of INR700cr (post tax) from sale of non-core asset sale of China unit. Sales proceeds is expected to be received by around August 2020, money will be utilised to reduce debt
- Management is searching for buyers for both fibre glass unit in Europe and Dubai unit. Ready to accept distressed valuation for Europe unit. Company expects Dubai unit to either be sold by Q2FY21 or will be integrated to existing operations
- Company expects inflow of ~INR300cr from the sale of above non-core assets
- Management expects robust cash flows to aid further net debt reduction
- Company does not expect any further reduction in working capital & target leverage at or below 1.0x.

- Company does not expect further benefits to be realized from lower fuel/pet-coke prices as they have stabilized. Current procurement prices for pet-coke is at ~\$70-75/MT (landed)
- Diesel prices are up ~15% since April 2020 but were stable YoY in Q1FY21
- Green power mix which has reached to ~14% is costing less than 20% of current costs, plans to increase to ~22-23% going forward
- Expect capex for FY21e INR1500 cr, including INR750-800cr of maintenance capex
- FY21e capex includes, ongoing expansion, 66MW WHRS across various locations, railway sidings, Bichara coal block, RMC plants and bulk terminal in Mumbai

Nestle India

Nestle India reported a 11.15 per cent rise in net profit of the quarter ended June to INR486.60 crore. The maker of Maggi Noodles had reported a net profit of INR437.8 crore in the same quarter a year ago. Total sales came in at INR3,041.5 crore, compared with INR2,982.8 crore a year ago. The past three months have witnessed volatility, uncertainty and stresses that we had never imagined before nor experienced. This led to disruptions across the value chain of the company that has impacted our results, though we have built back momentum strongly as we ended the quarter. Nestle India's domestic sales were up 2.6% over year ago at INR2,908 crore, while its exports were down 8.8% at INR134 crore.

IndusInd Bank

IndusInd Bank reported a 64.37 per cent year-on-year (YoY) fall in consolidated net profit at INR510.34 crore for the quarter ended June 30. The lender had posted a net profit of INR1,432.50 crore in the corresponding quarter last year. The net interest income (NII) for the quarter was at INR3,309 crore against the estimates of INR3,100 crore. The NII in the corresponding quarter last year was at INR2,844 crore. Total provisions for Q1FY21 was at INR2,259 crore, against INR2,440 crore kept aside in the previous quarter. A year ago, the provisions were at INR431 crore. The gross bad asset ratio spiked to 2.53 per cent from 2.45 per cent in March quarter and 2.15 per cent in June quarter last year.

Castrol India

Castrol India's standalone net profit slumped 64.2% to INR65.40 crore on 52.08% fall in total income to INR505.80 crore in Q2 June 2020 over Q2 June 2019. Castrol India said that disruptions owing to the Covid-19 pandemic escalated in the second quarter of 2020, resulting in a continued slowdown of the economy including decline in lubricants consumption. Robust working capital management, along with judicious cost management and efficiency programmes have helped us maintain a current strong liquidity and financial position to be able to meet any near-term challenges. Castrol India manufactures and markets automotive and industrial lubricants and specialty products. The company's products include lubricating oils, greases and brake fluids.

Sanofi India

Sanofi India reported a net profit of INR136.3 crore for the second quarter ended June 30, 2020. The company had posted a net profit of INR97.4 crore for the corresponding period of the previous fiscal. Revenue from operations stood at INR710.5 crore for the quarter under consideration. It was INR747.9 crore for the same period year ago. The financial results for the quarter ended June 30, 2020, are not comparable with that of corresponding quarter in 2019 due to completion of slump sale transaction on May 29, 2020, which resulted in transfer of Ankleshwar manufacturing facility and few products to Zentiva Private Limited. For the June quarter, the company has reported a drop in the sales by 5 per cent. Some therapy areas were impacted negatively due to the COVID-19 restrictions.

IDFC First Bank

IDFC First Bank reported net profit rise to INR93.5 crore at the end of June compared with a loss of INR617 crore during the same period last year. At the end of June, the bank had provided moratorium to about 28% of its customers based on the value, out of which 23% is in retail assets including rural portfolio and 35% is in the wholesale financing portfolio. We have liberally provided moratorium to customers who sought it, and our moratorium was about 45% last quarter, this has reduced to 28% now, which we expect to fall below 10% by August 31, 2020, based on the strong improving trend in collections we are experiencing. The provision at the end of the June quarter was at INR764 crore as compared to INR1,281 crore during last year and as compared to INR679 crore in Q4 FY20. In the first phase of moratorium, the Bank took coronavirus related provision of INR225 crore, during the June quarter the lender created additional coronavirus related provision of INR375 crore to further strengthen the balance sheet. The gross NPA of the bank reduced to 1.99% for the quarter under review, this was 2.66% same period a year ago. Net NPA stood at 0.51%. Apart from the NPA, the identified stressed asset pool of the bank, reduced by INR943 crore during the last financial year. This stressed pool stood at INR3,195 crore as of 30 June 2020 against which the Bank has done provisioning of INR1,668 crore, 52% of the pool.

Dr Reddy's

Dr Reddy's Laboratories posted a 12.59 per cent year-on-year (YoY) drop in net profit at INR579.30 crore for the quarter ended June 30. It had posted a net profit of INR662.80 crore in the corresponding quarter last year. Consolidated revenue increased by 14.93 per cent YoY to INR4,417.50 crore during the quarter under review. The current quarter's financial performance has been strong across all parameter. We have been able to serve our patients well and ensured continuity of business operations despite the challenging times. The company has started integration of the acquired business from Wockhardt and executed two important licencing arrangements for treatment options for Covid-19. At present, Dr Reddy's is working towards bringing both these drugs to multiple markets. The company paid income tax of INR299.60 crore, up 60 per cent, against INR187.20 crore in the same period last year. R&D as percentage of revenue stood at 9 per cent in Q1FY21 over 9.4 per cent in Q1FY20.

Maruti Suzuki

Maruti Suzuki India reported a standalone net loss of INR249.4 crore in the quarter ended June 2020 against profit of INR1,435.5 crore a year ago, hurt by Covid-19-induced lockdown. Sales for India's top car maker plunged to INR3,677.5 crore, from INR18,735.2 crore a year ago. Its operations and financial results for the quarter ended June have been adversely impacted by the outbreak of COVID-19 pandemic and the consequent lockdown due to which the operations were suspended for part of the quarter and gradually resumed with requisite precautions. The company sold a total of 76,599 vehicles during the quarter, sharply lower from 4,02,594 in the same quarter a year ago. Sales in the domestic market stood at 67,027 units, while exports were at 9,572 units. In developing the assumptions relating to the possible future uncertainties in the global economic conditions because of this pandemic, the group, as at the date of approval of these financial results, has used internal and external sources on the expected future performance.

Carborundum Universal Ltd

Consolidated net revenue of Carborundum Universal Ltd in Q1FY21 stood at INR449.58cr, which declined by 33.04% yoy from INR671.4cr in Q1FY20. EBITDA stood at INR43.37cr in Q1FY21 which decreased by 54.46% yoy. For Q1FY20, it had posted EBITDA of INR95.24cr. EBITDA margin as of Q1FY21 was at 9.65% which declined by 4.54% yoy compared to the same quarter, the previous year. The consolidated net profit in Q1FY21 came in at INR19.25cr which declined by 62.55%, as compared to Q1FY20, when it had reported INR51.4cr. The net profit margin in Q1FY21 came in at 4.28% which declined by 3.38% yoy. The net profit margin for Q1FY20 was at 7.66%.

Colgate-Palmolive

Colgate-Palmolive India Ltd (CPIL) reported a 17.18 per cent increase in net profit at INR198.18 crore for the quarter ended June 30, 2020, helped by lower expenses. The company had posted a net profit of INR169.11 crore in the April-June quarter last fiscal. Its total income during the quarter under review stood at INR1,046.90 crore, down 4.82 per cent from INR1,100.03 crore reported in the corresponding quarter a year ago. Its total expenses were at INR780.01 crore in the first quarter of 2019-20, down 6.83 per cent, as against INR837.22 crore reported in the corresponding period a year ago.

Manappuram Finance

Consolidated net revenue of Manappuram Finance in Q1FY21 stood at INR1,512.53cr, which rose by 27.03% yoy from INR1,190.69cr in Q1FY20. EBITDA stood at INR1099.58cr in Q1FY21 which rose by 30.53% yoy. For Q1FY20, it had posted EBITDA of INR842.41cr. EBITDA margin as of Q1FY21 was at 72.7% which rose by 1.95% yoy against the same quarter, the previous year. The consolidated net profit in Q1FY21 came in at INR367.97cr which rose by 37.93%, as compared to Q1FY20 when it had reported INR266.78cr. The net profit margin in Q1FY21 came in at 24.33% which rose by 1.92% yoy. The net profit margin for Q1FY20 was at 22.41%.

InterGlobe Aviation

InterGlobe Aviation-owned IndiGo airline reported standalone net loss of INR2,844.3 crore for June quarter of FY21 (Q1FY21), compared to profit of INR1,203 crore clocked in the previous-year quarter. On a quarterly basis, the loss widened 226.5 per cent from INR871 crore incurred in the March quarter of FY20. Closure of scheduled operations till May 24, 2020 and lower capacity deployment thereafter on account of Covid-19, significantly impacted the quarterly results. IndiGo reports net loss of INR2,844.3 crore. The loss before tax stood at INR2,842.6 crore for Q1FY21. The Gurugram-based airline's revenue from operations came in at INR766.7 crore for the quarter under revenue, down 91.8 per cent year-on-year (YoY), from INR9,420.1 crore reported in Q1FY20. It declined 90.7 per cent from revenue of INR8,299.1 crore earned in Q4FY20. Including other income of INR377.1 crore, total revenue came in at INR1,143.8 crore, down 88.3 per cent YoY, from INR9,786.9 crore reported in Q1FY20. IndiGo had a total cash balance of INR18,449.8 crore comprising INR7,527.6 crore of free cash and INR10,922.2 crore of restricted cash. Management of cash is of vital importance for the company as industry bodies have said normal passenger levels may come as late as 2024. The capitalized operating lease liability was INR21,177.9 crore while the total debt (including the capitalized operating lease liability) was INR23,551.6 crore.

Bharat Forge to raise INR500 crore via NCDs

Bharat Forge board has approved proposal to raise INR500 crore by issuing securities on a private placement basis. The company's board has discussed and approved the issuance of 5,000 listed, rated, unsecured, redeemable, non-convertible debentures (NCDs) of face value INR10 lakh each aggregating to INR500 crore on a private placement basis.

ITC drags Godfrey Phillips to court over infringement of its mark 'Flake'

In a major relief to cigarette maker ITC the Bombay High Court has restrained Godfrey Phillips (India) from manufacturing, distributing or selling its cigarette brand that contains the mark 'Flake' until further order. ITC, the Kolkata-based tobacco major claimed it is infringing its brand Flake Refined Taste. ITC had approached the court to restrain the Godfrey Phillips from infringing their copyright, and also from infringing company's registered trademark 'Flake', which according to the company has enjoyed the gross sales of around INR6,603 crore during FY 2018-19. ITC claims that the Mumbai-based company has launched new 'deceptively similar' packaging of its existing brand 'Select' to piggyback on its popular cigarette brand.

NTPC achieves highest-ever daily gross generation of 977.07 million units on July 28

State-run power giant NTPC achieved its highest-ever daily gross generation of 977.07 million units (MU) on July 28, 2020. This includes power generated from NTPC's subsidiaries and JV companies. NTPC's previous best daily generation was 935.46 MU achieved on March 12, 2019. With a total installed capacity of 62,910 MW, the NTPC Group has 70 power stations comprising 24 coal, seven combined cycle gas/liquid fuel, one hydro, 13 renewables along with 25 subsidiary and JV power stations.

Sanofi, GSK to supply up to 60 million doses of Covid-19 vaccine to UK

Sanofi and GSK had reached an agreement with Britain to supply it with up to 60 million doses of a potential COVID-19 vaccine, and that discussions with other governments were ongoing. No vaccine has yet been approved to treat or prevent COVID-19, the respiratory disease caused by the new coronavirus which has killed more than 659,000 people and triggered economic havoc worldwide. Financial terms of the agreement were not disclosed. Sanofi and GSK, which had first teamed up in April, confirmed in a statement that regulatory approval for their vaccine could be achieved by the first half of 2021 if clinical data was to be positive. The first clinical trials are expected in September. The vaccine will be developed by combining Sanofi's S-protein COVID-19 antigen and GSK's pandemic adjuvant technology. Adjuvants are efficacy boosters that play a vital role in many vaccines. An adjuvant is added to some vaccines to enhance the immune response, and has been shown to create a stronger and longer lasting immunity against infections than a vaccine alone.

CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Hero MotoCorp Ltd	Cash dividend of INR25 effective 30-07-20
Hindustan Unilever Ltd	Cash dividend of INR9.5 effective 30-07-20
Whirlpool of India Ltd	Cash dividend of INR5 effective 30-07-20
Kvantum Papers Ltd	Cash dividend of INR2.5 effective 30-07-20
Essel Propack Ltd	Cash dividend of INR2.05 effective 30-07-20
Balaji Amines Ltd	Cash dividend of INR0.6 effective 30-07-20

Domestic Events

- **Upcoming Result:-** Ajanta Pharma, Dabur, Deep Industries, GE Shipping, HDFC, Kirloskar Oil Engines, Laurus Labs, LT Foods, Mahindra Logistics, Max Financial Services, RIL, Torrent Pharmaceuticals

Global Events

- Japan Retail Sales for June 2020.
- The U.S. Fed Press Conference.
- The U.S. GDP for Q2 2020.
- The U.S. Initial Jobless Claims for July 25, 2020.
- Euro Area Unemployment Rate for June 2020.
- Euro Area Consumer Confidence for July 2020.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

Analyst Certification:

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

Terms & Conditions and Other Disclosures:

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.

The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at www.nseindia.com and/or www.bseindia.com, www.mcxindia.com and/or www.icex.com.

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

Sudipto Datta, Compliance Officer

SMIFS Limited.

Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.

Contact No.: +91 33 4011 5414 /91 33 6634 5414

Email Id.: compliance@smifs.com

Website: www.smifs.com